Results 131 to 140 of about 19,810 (202)

Post-marketing safety profile of bictegravir/emtricitabine/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis. [PDF]

Virol J
Xie Y, Luo Y, Chen Y, Shi G, He Y, Liu X, Cui Z, Zou F, Zhu C.   +8 more
europepmc   +1 more source

A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). [PDF]

Clin Infect Dis
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM.   +15 more
europepmc   +1 more source

Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide Study. [PDF]

J Korean Med Sci
Lim J, Yang J, Kim YJ, Kim HJ, Choi J.
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. [PDF]

Sci Rep
Shi F, Xia H, Weissman S, Li X, Yang X.
europepmc   +1 more source

A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks. [PDF]

AIDS
Stephen ZR, Perazzolo S, Duan L, Eguchi M, Tian B, Klein K, Kinman L, Delle Fratte R, Adams Waldorf KM, Barton T, Melvin AJ, Ho RJY.   +11 more
europepmc   +1 more source

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High-Replicative Low-Inflammatory Phase: A 48-Week Randomized Controlled Trial. [PDF]

J Med Virol
Luo Q, Xu R, Zhang Y, Xu W, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L.   +12 more
europepmc   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy. [PDF]

HIV Med
Sheridan R, Osei-Kuffour Ekert Y, Campbell L, Zuckerman M, Hawkins S, Childs K, Post FA.   +6 more
europepmc   +1 more source

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models. [PDF]

Aliment Pharmacol Ther
Kumada T, Atsukawa M, Itokawa N, Arai T, Toyoda H, Tsubota A, Watanabe T, Chuma M, Matsuura K, Hiraoka A, Tada T, Takaguchi K, Kato K, Abe H, Tani J, Ishikawa T, Ogawa C, Asano T, Oikawa T, Matsumoto Y, Akita T, Tanaka J.   +21 more
europepmc   +1 more source

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Treatment-Naive Patients Living With Human Immunodeficiency Virus (HIV) With High Viral Load: A Retrospective Observational Study. [PDF]

Cureus
Öztürk Belik H, Şimşek S, Kazak E, Ağca H, Heper Y, Budak F, Yılmaz E, Oral HB, Akalın H.   +8 more
europepmc   +1 more source